---
title: "inotuzumab"
slug: "inotuzumab"
date: "2023-05-25"
enableToc: false
tags:
- building
---

> [!info]
>
> 🌱 來自: [[relapse refractory of treatment of acute lymphoblastic leukemia (ALL)]]

# inotuzumab

* Inotuzumab ozogamicin
* Besponsa
* CD22單株抗體與 ozogamicin組成的ADC，

* 美國FDA於2017年8月核准inotuzumab ozogamicin用於復發或頑固型前驅B細胞ALL （Pre B-cell ALL, relapsed or refractory）的治療。
